Physician profile
Jack Vibbert
NPI 1063924868
$14,255.98
in general payments reported to CMS, 2019-2025
47 companies · $2,890 in 2025
The $2,890 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.35 · 2020: $421 · 2021: $2,030 · 2022: $2,633 · 2023: $3,086 · 2024: $3,183 · 2025: $2,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,158.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,401.97 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,314.36 | 2021-2025 | |
| Lilly USA, LLC | $1,285.91 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,158.15 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $899.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $885.82 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $747.06 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $695.63 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $665.30 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $373.79 | 2020-2022 | |
| Corium, LLC | $372.28 | 2023-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $281.45 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $278.56 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.44 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $236.59 | 2020-2024 | Nexletol |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Vibbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.